Inclusion Criteria:

          -  Inclusion Criteria for participants enrolling into Cohort 1:

          -  Study participants have documented persistent, recurrent, or metastatic squamous cell
             carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix

          -  Study participants have not been treated with systemic chemotherapy and are not
             amenable to curative treatment

          -  Prior radiation with or without radio-sensitizing chemotherapy is allowed

          -  Inclusion Criteria for participants enrolling into Cohort 2:

          -  Participants have documented evidence of cervical adenocarcinoma, squamous cell
             carcinoma, or adenosquamous carcinoma International Federation of Gynecology and
             Obstetrics (FIGO) 2018 Stages 1B2 to 4A

          -  Participants have not received prior chemotherapy or radiotherapy for cervical cancer

          -  Inclusion Criteria for all participants:

          -  Archival tumor tissue sample or newly obtained core or excisional biopsy is required

          -  Participants who have Eastern Cooperative Oncology Group (ECOG) Performance status
             (PS) of 0 to 1

          -  Participants have a life expectancy greater than or equal to 12 weeks

          -  Participants have adequate hematological, hepatic, renal and coagulation function as
             defined in the protocol

          -  Participants with known Human immunodeficiency virus (HIV) infections are eligible if
             the criteria described in the protocol are met

          -  Participants with Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) infections
             are eligible if the criteria described in the protocol are met

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Exclusion Criteria for All Participants:

          -  Participants with active central nervous system (CNS) metastases causing clinical
             symptoms or metastases that require therapeutic intervention are excluded.Participants
             with a history of treated CNS metastases (by surgery or radiation therapy) are not
             eligible unless they have fully recovered from treatment, demonstrated no progression
             for at least 4 weeks, and are not using steroids for at least 7 days prior to the
             start of study intervention

          -  Participants that received any organ transplantation, including allogeneic stem-cell
             transplantation, but with the exception of transplants that do not require
             immuno-suppression

          -  Participants with significant acute or chronic infections

          -  Participants with active autoimmune disease that might deteriorate when receiving an
             immuno-stimulatory agent

          -  Participants with clinically significant cardiovascular/cerebrovascular disease
             including: cerebral vascular accident/stroke, myocardial infarction, unstable angina,
             congestive heart failure, or serious cardiac arrhythmia

          -  Participants with history of bleeding diathesis or recent major bleeding events

          -  Participant that has received prior cancer treatment with any other immunotherapy or
             checkpoint inhibitors or any other immune-modulating monoclonal antibody (mAb)

          -  Exclusion Criteria for Participants in Cohort 1A related to use of bevacizumab:

          -  Participants with inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Participants with significant vascular disease within 6 months prior to Screening

          -  Participants with history of hemoptysis within 1 month prior to Screening

          -  Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for
             therapeutic purposes

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to the first dose of bevacizumab

          -  Participants with a history of abdominal or trache-oesophageal fistula or
             gastrointestinal (GI) perforation within 6 months prior to Screening

          -  Participants with clinical signs of GI obstruction or requirement for routine
             parenteral hydration, parenteral nutrition, or tube feeding

          -  Participants with evidence of abdominal free air not explained by paracentesis or
             recent surgical procedure

          -  Participants with serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Participants with proteinuria

          -  Other protocol defined exclusion criteria could apply